Author Interviews, Blood Pressure - Hypertension, COVID -19 Coronavirus / 01.04.2020
Blood Pressure Meds ACEIs and ARBs and COVID-19 Infection
MedicalResearch.com Interview with:
[caption id="attachment_53718" align="alignleft" width="200"]
Dr. Sanchis-Gomar[/caption]
Fabian Sanchis-Gomar, MD, MSc, PhD
Department of Medicine
Stanford University Medical Center
Stanford, California
Department of Physiology, School of Medicine, University of Valencia
INCLIVA Biomedical Research Institute
Valencia, Spain
MedicalResearch.com: What is the background for this study? How does the RAAS system interface with the COVID-19 virus?
Response: Angiotensin-converting enzyme (ACE)2 is a functional receptor for coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The exponential growth of contagion by the SARS-CoV-2 all around the world has contributed to raising speculations and concerns about whether two commonly used anti-hypertensive drugs, i.e., ACE inhibitors and angiotensin receptor blockers (ARBs), have positive or negative effects in coronavirus disease 2019 (abbreviated “COVID-19”) patients with arterial hypertension on-going treatment with some of the former drugs.
In effect, many professional health organizations have published statements claiming that there is not enough evidence to change the use of ACE-inhibitors or ARBs for the management of raised blood pressure (BP) in the context of avoiding or treating COVID-19 infection.
Dr. Sanchis-Gomar[/caption]
Fabian Sanchis-Gomar, MD, MSc, PhD
Department of Medicine
Stanford University Medical Center
Stanford, California
Department of Physiology, School of Medicine, University of Valencia
INCLIVA Biomedical Research Institute
Valencia, Spain
MedicalResearch.com: What is the background for this study? How does the RAAS system interface with the COVID-19 virus?
Response: Angiotensin-converting enzyme (ACE)2 is a functional receptor for coronaviruses, including Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). The exponential growth of contagion by the SARS-CoV-2 all around the world has contributed to raising speculations and concerns about whether two commonly used anti-hypertensive drugs, i.e., ACE inhibitors and angiotensin receptor blockers (ARBs), have positive or negative effects in coronavirus disease 2019 (abbreviated “COVID-19”) patients with arterial hypertension on-going treatment with some of the former drugs.
In effect, many professional health organizations have published statements claiming that there is not enough evidence to change the use of ACE-inhibitors or ARBs for the management of raised blood pressure (BP) in the context of avoiding or treating COVID-19 infection.


Dr. Bin Cao[/caption]
Bin Cao, Yeming Wang, Guohui Fan,
Lianghan Shang, Jiuyang Xu, DingyuZhang, Chen Wang
on behalf of LOTUS-China Study Group
China-Japan Friendship Hospital; Wuhan Jintinyan Hospital;
Institute of Respiratory Medicine, Chinese Academy of Medical Science
MedicalResearch.com: What is the background for this study?
Response: In the past two months, the outbreak of Coronavirus Disease 2019 (COVID-19) has been spreading rapidly across the world. Science and technology is the most powerful weapon for human to fight against diseases, especially in such a pandemic setting. Seeking for effective antiviral medication is the most critical and urgent among the many scientific tasks in the pandemic.
At the most critical moment in the fight against COVID-19, Chinese clinical scientists have stepped forward under extremely difficult research conditions to carry out clinical trials in antiviral treatment including lopinavir–ritonavir and remdesivir, in a swift, decisive and effective manner. These trials have attracted worldwide attention.
Recently, the Lopinavir–ritonavir Trial for suppression of SARS-CoV-2 in China (LOTUS-China) has been completed, which, with great clinical significance, can provide strong evidence for the treatment of COVID-19 both in China and around the world.



Dr. Jeffrey Smith[/caption]
Jeffrey R. Smith, MD PhD
Department of Medicine, Division of Genetic Medicine
Vanderbilt-Ingram Cancer Center, and Vanderbilt Genetics Institute
Vanderbilt University Medical Center
Medical Research Service
Tennessee Valley Healthcare System, Veterans Administration
Nashville, TN
MedicalResearch.com: What is the background for this study?
Response: Roughly 20% of men with prostate cancer have a family history of the disease, and 5% meet criteria for hereditary prostate cancer. Although prostate cancer has the greatest heritability of all common cancers (twice that of breast cancer), extensive heterogeneity of its inherited causes has presented a considerable obstacle for traditional pedigree-based genetic investigative approaches. Inherited causes across, as well as within families are diverse.
This study introduced a new familial case-control study design that uses extent of family history as a proxy for genetic burden. It compared a large number of men with prostate cancer, each from a separate family with a strong history of the disease, to screened men with no personal or family history. The study comprehensively deconstructs how the 8q24 chromosomal region impacts risk of hereditary prostate cancer, introducing several new analytical approaches. The locus had been known to alter risk of prostate, breast, colon, ovarian, and numerous additional cancers.




